In the endemic phase of COVID-19, SARS-CoV-2 continues to inflict an unacceptable burden on humankind. After millions of deaths, billions of infections, unprecedented disease burden, enormous economic costs, and long COVID-19 we continue to see major needs and opportunities. Progress with vaccines and therapeutics has been encouraging while variants of concern continue to plague progress, and the specter of new pandemics haunts our future. We invested in Invivyd, led by world renowned experts in monoclonal antibody design, which is developing a portfolio of broadly neutralizing antibodies to address pandemic and endemic SARS-COV-2 and other viruses of pandemic potential.